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Cancer genomes exhibit numerous deletions, some
of which inactivate tumor suppressor genes and/or
correspond to unstable genomic regions, notably
common fragile sites (CFSs). However, 70%–80%
of recurrent deletions cataloged in tumors remain
unexplained. Recent findings that CFS setting is
cell-type dependent prompted us to reevaluate
the contribution of CFS to cancer deletions. By
combining extensive CFS molecular mapping and a
comprehensive analysis of CFS features, we show
that the pool of CFSs for all human cell types consists
of chromosome regions with genes over 300 kb long,
and different subsets of these loci are committed to
fragility in different cell types. Interestingly, we find
that transcription of large genes does not dictate
CFS fragility. We further demonstrate that, like
CFSs, cancer deletions are significantly enriched in
genes over 300 kb long. We now provide evidence
that over 50% of recurrent cancer deletions originate
from CFSs associated with large genes.
INTRODUCTION
Common fragile sites (CFSs) are megabase-long loci that recur-
rently exhibit instability, visible as breaks on mitotic chromo-
somes following perturbation of DNA replication (Durkin and
Glover, 2007). CFSs drive chromosomal rearrangements in
tumors (Beroukhim et al., 2010; Bignell et al., 2010), which may
favor oncogenesis upon inactivation of tumor suppressor genes
hosted by some of these sites (Iliopoulos et al., 2006; Saldivar
et al., 2012) and/or amplification of some oncogenes (Coquelle
et al., 1997).
It is largely agreed that CFSs remain incompletely replicated
until mitotic onset upon replication stress, making them prone420 Cell Reports 4, 420–428, August 15, 2013 ª2013 The Authorsto breakage (Durkin and Glover, 2007). Recent studies of four
major CFSs have shown that a specific replication program
combining late replication with failure to activate origins along
the core of the sites is responsible for their delayed replication
completion (Le Tallec et al., 2011; Letessier et al., 2011).
Because replication programs evolve along with cell differentia-
tion (Me´chali, 2010; Ryba et al., 2010), different chromosomal
regions can be committed to fragility in different cell types, as
illustrated by the different repertoires of CFSs found in human
fibroblasts and lymphocytes (Debatisse et al., 2012).
Human CFSs have only been localized in lymphocytes and
fibroblasts thus far, which provides a restricted view of the
CFS landscape. How many CFSs are present in the human
genome and how many are shared by different cell types remain
unknown. Answering these questions is required to reevaluate
the importance of CFSs in rearrangements found in tumors orig-
inating from different cell types. Interestingly, pioneering work
fromD.I. Smith’s group showed that several CFSs overlap genes
spanning extremely large genomic regions (hereafter referred to
as large genes) (Smith et al., 2007). Many recurrent focal dele-
tions in cancer genomes also target large genes, some of which
are associated with known CFSs (Dereli-O¨z et al., 2011). The
question therefore arises whether all the other unstable large
genes are also associated with yet to be identified CFSs.
In this study, we have extended CFS mapping to a wide range
of human cell lines including epithelial cells of breast and colon
from which most human cancers originate. Mapping was per-
formed at the molecular level and was combined with a com-
prehensive computational analysis to provide both a refined
characterization of CFSs and a precise assessment of their
contribution to cancer deletions.
RESULTS
Defining CFS Repertoires of Epithelial and Erythroid
Cells
We localized CFSs in six human cell lines, namely three MSI
colorectal cancer epithelial cell lines (LS174T, HCT116, and
(legend on next page)
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LoVo), nontumorigenic and cancer breast epithelial cells
(MCF10A and CAL51, respectively), and leukemia-derived
K562 erythroid cells. We conducted conventional cytogenetic
analyses on R-banded metaphase chromosomes from cells
treated with aphidicolin, an inhibitor of replicative DNA polymer-
ases. A chromosomal locus was considered to be fragile if
breaks at that site represented at least 1% of the total number
of breaks. With this threshold, breaks clustered on a dozen sites
in each cell line, representing approximately two-thirds of all
lesions (Figures 1A–1F; Table S1). These results are in line with
those reported for CFSs previously mapped in primary lympho-
cytes (Mrasek et al., 2010) and fibroblasts of fetal lung or dermal
origin (Le Tallec et al., 2011; Murano et al., 1989).
We first compared CFSs newly mapped in the six cell lines
(Figure 1G). We found that epithelial cells share, on average,
36% of their CFSs. In contrast, epithelial and erythroid cells
have only 14% of their CFSs in common. Cell lines of the same
cell type thus tend to share a larger part of their CFSs than cell
lines of different cell types. Using the same conditions of cytoge-
netic analysis as those used above, we found that 45% of
the CFSs are conserved between primary lymphocytes from
different individuals, which is similar to the conservation of
CFSs in primary dermal fibroblasts (48%; Table S2) calculated
by reanalyzing the published data (Murano et al., 1989). The
group of epithelial cells thus displays differences comparable
to the interindividual variability measured in primary lymphocytes
and dermal fibroblasts. This suggests that changes accompa-
nying cancer development do not massively impact the CFS
setting, although it is possible thatmutations in DNA repair genes
or deletions in unstable regions may affect the break frequency
of some CFSs in those cell lines. Combining our results with
data from primary lymphocytes (Mrasek et al., 2010) and fibro-
blasts (Le Tallec et al., 2011; Murano et al., 1989), we calculate
that two different cell types share less than 20% of their CFSs
(Figure 1G), which emphasizes that CFS setting is cell-type
dependent, i.e., is defined epigenetically.
Interestingly, although CFS repertoires differ extensively from
one cell type to another, the comparison of CFSs with a break
frequency over 1% in epithelial cells, erythroid cells, fibroblasts,
and lymphocytes showed that 21 out of 49 CFSs (43%) are frag-
ile in at least two cell types (Figure 1H). This result suggests that
these loci share features predisposing them to fragility. However,
in agreement with the epigenetic nature of CFSs, we find that the
frequency of a given CFS can vary greatly across the cells in
which it is fragile (Figure 1I). For example, FRA16D, which is frag-
ile in all cell lines, accounts for more than 25% of all breaks in
MCF10A cells but for only 3% in K562 cells.Figure 1. Defining CFS Repertoires of Epithelial and Erythroid Cells
(A–F) Aphidicolin-induced breaks in six human cell lines are shown: three MSI colo
breast epithelial cells (MCF10A); cancer breast epithelial cells (CAL51); and K
nomenclature established in lymphocytes. Breaks at indicated CFSs are express
(G) The percentage of CFSs shared by different cell lines is presented. MRC5, fe
blood lymphocytes.
(H) CFSs with a break frequency over 1% in epithelial cells (HCT116, LoVo, LS1
fibroblasts), and lymphocytes. The presence of each CFS among the four cell ty
indicated. The total number of different CFSs is 49.
(I) Breakage frequencies of FRA3B, FRA7K, and FRA16D in different cell lines ar
See also Tables S1 and S2.
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300 kb Long
To decipher which features contribute to fragility, it is necessary
to map fragile regions at the molecular level by fluorescence
in situ hybridization (FISH). We therefore hybridized over
20,000 metaphase spreads of aphidicolin-treated cells with
BAC (bacterial artificial chromosome) probes delimitating candi-
date regions for 15 CFSs (Table S3). We found that 10 out of
these 15 CFSs are associated with one or several large genes
over 600 kb long (Table S4), which confirms and extends previ-
ous observations that many CFSs overlap genes ranging from
600 kb to more than 2 Mb (McAvoy et al., 2007a). In addition,
four out of the five remaining sites are associated with genes
from 366 to 582 kb in length (Table S4). This prompted us to
determine what is a ‘‘large gene’’ in the context of CFSs and
whether the association between CFSs and large genes is signif-
icant or occurs solely by chance. Indeed, given their size, large
genes extend over a large proportion of the genome. For
instance, genes over 600 kb represent only 0.8% of human
genes (Figure 2A) but cover more than 5% of the human genome
(data not shown). To address these issues, we took into account
CFSs mapped molecularly in this study and in previous work
(Table S4) and calculated whether the percentage of CFSs asso-
ciated with genes of a given length could be explained by
randomness. Strikingly, this analysis revealed a statistically
significant association of CFSs with genes over 300 kb long (Fig-
ure 2B; p = 0.017). This length threshold is 15 times higher than
themedian length of human genes (20.9 kb), with genes over 300
kb long accounting for 3.4% of all human genes (Figure 2A).
All CFSs conserved between human and mouse described so
far are associated with orthologous large genes, as exemplified
by the human FHIT gene in FRA3B and the murine Fhit in
Fra14A2 (Smith et al., 2007). To extend these results, we map-
ped CFSs by conventional cytogenetics in mouse embryonic
fibroblasts (MEFs). We found that all these CFSs reside within
chromosome bands hosting large genes (Table S1). This associ-
ation was confirmed at the molecular level for the three major
CFSs in MEFs (Table S4). Moreover, all large genes associated
with MEF CFSs have human orthologs, five of which being
now associated with human CFSs (Table S1; Smith et al., 2007).
CFSs have only been studied in mammals thus far (Durkin and
Glover, 2007), but analysis of sequenced genomes has revealed
that large genes associated with human CFSs are conserved in
various vertebrates, notably birds. Interestingly, we detected
recurrent breaks induced by aphidicolin in DT40 chicken
lymphoid cells (data not shown). Strikingly, our molecular map-
ping revealed that the most fragile region in DT40 cells isrectal cancer epithelial cell lines (HCT116, LoVo, and LS174T); nontumorigenic
562 erythroid cells. The names of human CFSs are given according to the
ed relative to the total number of breaks. See Table S1 for details.
tal lung fibroblasts; Dm. fibro., primary dermal fibroblasts; lympho., peripheral
74T, CAL51, MCF10A), erythroid cells (K562), fibroblasts (MRC5 and dermal
pes was recorded. The name of the CFSs identified in one to four cell types is
e shown.
Figure 2. CFSs Are Significantly Associated with Genes over 300 kb Long
(A) The number of human genes according to their length is shown. A total of 169 out of 21,357 genes (0.8%) and 716 out of 21,357 genes (3.4%) extend over 600
and 300 kb, respectively.
(B) Nonrandom association between genes over 300 kb long and the 49 CFSs mapped at the molecular level is presented. Dark-blue dots correspond to the
observed percentage of CFSs that overlap genes over the indicated length (genes ‘‘>0’’ correspond to all genes of the genome). The gray area delimits per-
centages of overlap between CFSs and genes resulting from a random positioning of the 49 CFSs in the genome (for example, CFSs randomly positioned in the
genome can overlap between 1.9% and 11.1% of the genes over 1,200 kb long). Thus, blue dots above, in, or below the gray area are the result of a respective
significant excess, random number, or significant paucity of CFSs overlapping genes. See the Extended Experimental Procedures for details.
(C) Distribution of replication timing of human genes in K562 cells with respect to a minimal gene length is shown. Replication timing of each gene (vertical axis)
was assessed by a score reflecting its average timing of replication along the cell cycle, with 0, 20, 40, 60, 80, and 100 corresponding to G1, S1, S2, S3, S4, and
G2, respectively. See the Extended Experimental Procedures for details. Boxes extend from the 25th to the 75th percentiles. Whiskers extend down to the
minimum and up to the maximum values. Horizontal black lines represent the median. The number of genes is indicated above each box. Repli-Seq data are not
available for some chromosome segments, which explains why the total number of genes is 20,501 instead of 21,357.
See also Figure S1 and Tables S3 and S4.orthologous to human FRA4F andmurine Fra6C1, this CFS being
associated in the three species with the large genes CCSER1
and GRID2 (Table S4; Durkin and Glover, 2007). Our data thus
highlight the conservation of human, murine, and avian CFSs
and suggest a causal role of large genes in this conservation.
We next asked if large genes have specific characteristics that
may predispose them to fragility. Because late replication is a
key feature of CFS instability (Debatisse et al., 2012), we first
analyzed the replication timing of human genes in three cell
types, namely erythroid cells, lymphocytes, and fibroblasts,
using available genome-wide timing profiles established by the
Repli-Seq technique (Hansen et al., 2010). Strikingly, we observe
a strong association between replication timing and gene length,showing that large genes tend to lie in late-replicating domains
(Figures 2C, S1A, and S1B). Importantly, such an association is
not found in a randomized data set (Figure S1C). We also find
that large genes show a high AT content (Figure S1D), a charac-
teristic displayed by most CFSs (Durkin and Glover, 2007).
In conclusion, our results demonstrate that the vast majority of
CFSs relate to the presence of genes over 300 kb long. Correla-
tively, they suggest that all genomic regions containing such
genes may be potential CFSs.
Transcription of Large Genes Does Not Dictate Fragility
A recent study of five CFSs associated with large genes has sug-
gested that collisions between replication forks and transcribingCell Reports 4, 420–428, August 15, 2013 ª2013 The Authors 423
(legend on next page)
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RNA polymerase II are responsible for their instability (Helmrich
et al., 2011). Surprisingly, whereas this model implies that breaks
should be confined to large genes, our molecular mapping of
CFSs revealed that fragile regions could be either precisely or
only partly nested within the cognate large gene(s) (Figures
3A–3C). For instance, all breaks at FRA10C occur within the
1.3-Mb-long PRKG1 gene in LoVo cells (Figure 3A), whereas
only 48% of the breaks at FRA20B localize within the 2-Mb-
long MACROD2 gene in LS174T cells, the other half being
scattered over a 3.5-Mb-long region extending 50 of the gene
(Figure 3B). These two situations were observed independently
of the length of the large genes associatedwith CFSs (Figure 3D).
These results suggest that there may be two distinct types of
CFSs. However, we repeatedly found that the molecular location
of a given CFS could vary between cell types or even between
cell lines originating from the same tissue (Figures 3B, 3C, and
S2A–S2C). For example, breaks at FRA20B occur almost
exclusively within MACROD2 in MCF10A cells, unlike what is
observed in LS174T (Figure 3B). This plasticity in break localiza-
tion seems hardly compatible with two classes of CFSs and,
rather, suggests that transcription units per se do not set the bor-
ders of CFSs. To determine whether the collision mechanism
could at least account for breaks occurring inside large genes,
we compared the frequency of breaks inside the 24 genes over
300 kb long associated with CFSs in HCT116 cells with their
expression levels measured by quantitative RT-PCR (qRT-
PCR). In contrast to the results from Helmrich et al. (2011), we
find no correlation between the mRNA levels of large genes
and their instability (Figure S2E). Moreover, the analysis of
RNA-seq data produced by the ENCODE Project Consortium
(2011) revealed that the vast majority of large genes expressed
in HCT116 cells are not associated with CFSs (Figure 3E).
Together, our results show that transcription of large genes
does not dictate the instability of cognate CFSs.
The Majority of Recurrent Cancer Deletions Originate
from CFSs
Two studies have cataloged recurrent focal deletions in large
cohorts of human tumors and cancer cell lines (Beroukhim
et al., 2010; Bignell et al., 2010). Although a portion of the recur-
rent deletions has been correlated with the presence of known
tumor suppressor genes or with CFSs, 70%–80% of them
remain unexplained. We find that the 15 CFSs mapped at the
molecular level in our study account for an additional 10% of
recurrent cancer deletions (Table S5). Notably, FRA20B overlaps
one of the most prevalent clusters of unexplained deletions in
human cancers (Figure 3B). These deletions precisely map in-Figure 3. Transcription of Large Genes Does Not Dictate Fragility
(A–C) Schematic representation of FRA10C (A), FRA20B (B), and FRA4D (C) is s
smaller or larger than 300 kb, respectively); chromosome band; BACs used in FIS
appeared left (L), inside (I), or right (R) to the hybridization signal; CFS localization (y
and deletion clusters [from Bignell et al., 2010], with the total number of deletion
Beroukhim et al., 2010]). Of note, chromosomal rearrangements have been report
2008). Only loci displaying the expected localization of FISH probes were analyz
(D) Break localization relative to genes over 300 kb long associated with CFSs is s
less than three-quarters of the breaks occur inside the gene. The number of gen
(E) Expression in fragments per kilobase per million reads (FPKM) of genes over
See also Figure S2.side the 2-Mb-long MACROD2 gene, namely the subregion of
FRA20B that we found unstable in different cell types. Other
deletions identified by Bignell et al. (2010) lie in regions flanking
MACROD2, which supports our finding that the fragile region is
not confined to the large gene. Although molecular mapping of
additional CFSs will undoubtedly extend the number of deletions
attributable to CFSs, we reasoned that the association between
CFSs and chromosome regions hosting large genes might be
reflected in deletions mapped in tumors. We therefore reana-
lyzed the data provided by Bignell et al. (2010) (Figures 4A, 4C,
and 4E) and Beroukhim et al. (2010) (Figures 4B, 4D, and 4F),
which first revealed that the proportion of genes overlapping
recurrent cancer deletions increases with gene length (Figures
4A and 4B). As illustrated in Figure 4C, 21 out of 28 genes
(75%) over 1,200 kb long overlap recurrent deletions mapped
by Bignell et al. (2010). Importantly, we observed an extensive
overlap between large genes associated with cancer deletions
and large genes associated with CFSs molecularly mapped
thus far (Figures 4A and 4B, dashed lines, and Figures 4C and
4D). In addition, it has been reported that eight of the ten most
frequent focal deletions in human cancers target large genes
(Dereli-O¨z et al., 2011). Not surprisingly, all but one of these large
genes have now been assigned to a CFS (Table S4; Dereli-O¨z
et al., 2011). Our results therefore suggest that all large genes
overlapping cancer deletions are associated with CFSs.
We next determined the minimal length of genes associated
with cancer deletions. We calculated that recurrent deletions
mappedbyBignell et al. (2010) nonrandomly occur in genomic re-
gions containing genes over 300 kb long (Figure 4E; p = 4.6 3
104), which is reminiscent of the results obtained for CFSs (Fig-
ure 2B). Strikingly, 56.4% of recurrent cancer deletions take
place in regions hosting such large genes (Figure 4E, dark-blue
line). Analysis of recurrent cancer deletions identified by Berou-
khim et al. (2010) gave consistent results (nonrandom overlap
of genes over 500 kb long, accounting for 51.4% of recurrent
cancer deletions, p = 0.017; Figure 4F). Together, our results
thus suggest that the majority of recurrent focal deletions found
in human cancers originate from loci hosting large genes that
are fragile in the cell types from which the cancer cells derive.
DISCUSSION
Our mapping of CFSs in epithelial and erythroid cells illustrates
the diversity of CFS repertoires found in different cell types and
in different isolates of the same tissue, which confirms results
we obtained previously in lymphocytes and fibroblasts (Le Tallec
et al., 2011; Letessier et al., 2011), emphasizing the epigenetichown. From top to bottom: RefSeq genes (dark and light blue indicate genes
H experiments (black line) with the frequency of metaphases where the break
ellow or orange lines); focal deletions in cancer cells (blue line shows singletons
s within the cluster indicated; violet line shows recurrent focal deletions [from
ed for some cell lines used in this study, for instance HCT116 cells (Alsop et al.,
ed.
hown. Genes were divided into two categories depending on whether more or
es for each minimal gene length is indicated.
300 kb long in HCT116 cells as measured by RNA-seq is presented.
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Figure 4. Analysis of the Association between CFSs, Large Genes and Recurrent Deletions Identified in Tumors
(A, C, and E) Analysis of recurrent cancer deletions identified by Bignell et al. (2010) on autosomal chromosomes is presented.
(B, D, and F) Analysis of recurrent cancer deletions identified by Beroukhim et al. (2010) is shown.
(legend continued on next page)
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nature of CFSs. In addition, our results show that virtually all
CFSsmolecularly mapped thus far relate to the presence of large
genes, and strongly suggest that CFS conservation in verte-
brates relies on the conservation of large genes. We demon-
strate here that this association, which has long been described
for extremely large genes (Smith et al., 2007), actually occurs
nonrandomly for genes over 300 kb long in humans and that
CFSs display features that are characteristic of large genes.
Our study also provides an example of a CFS associated with
a large nonprotein-coding gene (the 545-kb-long LINC00669
gene in FRA18A in LS174T cells, Figure S2D). Because an
increasing number of previously nonannotated RNAs are being
cataloged (Djebali et al., 2012), it is possible that the 15%–
20%of CFSs devoid of large genes host yet to be identified large
transcription units. In conclusion, we propose that chromosome
regions hosting genes over 300 kb long constitute the pool of
CFSs for all human cell types, a specific subset of these loci
being committed to fragility in a given cell type. The human
genome contains approximately 700 such genes (Figure 2A).
However, we observe that CFSs overlap, on average, 1.5 large
genes, which may theoretically decrease the size of the human
pool to approximately 450 loci.
The striking association of CFSs with large genes advocates a
causal role of those genes in fragility. Surprisingly, we find that
the proportion of breaks affecting the large gene itself or its flank-
ing regions is extremely variable from CFS to CFS. We also
observe some plasticity in the molecular localization of a given
CFS across cell types. Interestingly, deletions in cancer cells
mirror the localization of breaks inside or outside the large genes,
as exemplified by FRA20B or FRA4D (Figures 3B and 3C). These
results indicate that the large gene itself does not set the bound-
aries of a given CFS. Moreover, in contrast with a previous report
analyzing a small number of CFSs (Helmrich et al., 2011), we
show that the transcription status of large genes does not dictate
the fragility of cognate CFSs. Importantly, we find that even
genes larger than 800 kb that require more than one complete
cell cycle to be transcribed (Helmrich et al., 2011) are not inevi-
tably committed to fragility when they are expressed. Therefore,
although transcriptionmight contribute to the instability of certain
CFSs, we propose that fragility is primarily related to chromo-
somal organization rather than transcription per se. Interestingly,
a strong link between replication timing and chromatin domains
identified by genome-wide chromatin interaction studies has
been observed by Ryba et al. (2010). Large genes, via the asso-
ciation of their transcription regulatory elements, may contribute
to organize flexible chromatin domains that govern local replica-
tion timing and origin density in a given cell type, two parameters
controlling CFS stability (Letessier et al., 2011).
The prevalence of certain CFSs is expected to impact the
number of deletions found at the cognate loci in tumors from
various origins. Indeed, the observation that FRA16D and(A and B) The percentages of genes overlapping recurrent deletions in tumors, C
length are illustrated.
(C and D) Venn diagrams of overlap between genes over 1,200 kb long, recurrent d
number of genes in each class is indicated.
(E and F) Nonrandom association between large genes and recurrent deletions i
See also Table S5.FRA3B are fragile in every or virtually every cell type where
CFSs have been mapped agrees with studies showing that
they are among the top regions of the human genome affected
by deletions in cancer cells (Dereli-O¨z et al., 2011). The fact
that both FRA3B and FRA16D overlap tumor suppressor genes
likely also contributes to the selection of cells with deletions in
these sites (Iliopoulos et al., 2006; Saldivar et al., 2012).
Conversely, CFSs that are found in a limited number of cell types
will unlikely show up as major rearranged regions in global ana-
lyses of large cohorts of many different cancer classes. How-
ever, they can be detected in studies focusing on specific types
of tumors as shown recently for FRA1F in bladder cancer (Sche-
peler et al., 2012). Importantly, like CFSs, cancer deletions are
significantly enriched in genes over 300 kb long, and we have
demonstrated that the extensive overlap between CFSs and
cancer deletions relies on their mutual association with large
genes. We have also shown that late replication, one of the
most documented features of CFSs, is a characteristic of large
genes. Accordingly, it has recently been shown that late-repli-
cating regions are enriched in cancer deletions (De and Michor,
2011). Together, these results strongly suggest that recurrent
cancer deletions overlapping large genes originate from CFSs,
which explains more than half of recurrent deletions found in
tumors. Recently identified early-replicating fragile sites (Barlow
et al., 2013) or regions encompassing high densities of negative
regulators of cell proliferation (Solimini et al., 2012) could explain,
at least in part, the remaining recurrent deletions.
EXPERIMENTAL PROCEDURES
Experimental Procedures and any associated references are available in the
Extended Experimental Procedures. See also Figure S3.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, three
figures, and five tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.celrep.2013.07.003.
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